We are live on ! Find out more
SCMP

Sucampo Pharmaceuticals, Inc.
SCMP

Delisted

SCMP was delisted on the 12th of February, 2018.

149 hedge funds and large institutions have $383M invested in Sucampo Pharmaceuticals, Inc. in 2015 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 62 increasing their positions, 48 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 48

25% more call options, than puts

Call options by funds: $1.01M | Put options by funds: $807K

3% less funds holding

Funds holding: 154149 (-5)

16% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 25

18% less capital invested

Capital invested by funds: $468M → $383M (-$84.9M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
149
Holders Change
-5
Holders Change %
-3.25%
% of All Funds
3.91%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
21
Increased
62
Reduced
48
Closed
25
Calls
$1.01M
Puts
$807K
Net Calls
+$201K
Net Calls Change
+$935K
Name Holding Trade Value Shares
Change
Change in
Stake
Marshall Wace
76
Marshall Wace
United Kingdom
$562K +$583K +32,525 New
Tudor Investment Corp
77
Tudor Investment Corp
Connecticut
$536K -$285K -15,917 -34%
PCM
78
Piermont Capital Management
Missouri
$531K -$36.9K -2,060 -6%
Swiss National Bank
79
Swiss National Bank
Switzerland
$501K
BG
80
BlackRock Group
United Kingdom
$499K -$3.23K -180 -0.6%
DC
81
Deere & Company
Illinois
$481K +$10.4K +578 +2%
GF
82
Gerstein Fisher
New York
$467K -$2.28K -127 -0.5%
RhumbLine Advisers
83
RhumbLine Advisers
Massachusetts
$453K +$56.9K +3,175 +14%
NA
84
Navellier & Associates
Nevada
$428K -$203K -11,323 -31%
CCM
85
Cadence Capital Management
Massachusetts
$420K -$30.4K -1,693 -7%
DekaBank Deutsche Girozentrale
86
DekaBank Deutsche Girozentrale
Germany
$407K +$5.38K +300 +1%
Bank of Montreal
87
Bank of Montreal
Ontario, Canada
$406K +$300K +16,708 +245%
Citigroup
88
Citigroup
New York
$396K +$222K +12,375 +117%
PPA
89
Parametric Portfolio Associates
Washington
$367K +$39.7K +2,214 +12%
BCM
90
Bridgeway Capital Management
Texas
$346K -$8.96K -500 -2%
Royal Bank of Canada
91
Royal Bank of Canada
Ontario, Canada
$341K +$345K +19,250 +4,036%
AL
92
Airain Ltd
Guernsey
$335K +$348K +19,386 New
Squarepoint
93
Squarepoint
New York
$322K +$333K +18,600 New
MLICM
94
Metropolitan Life Insurance Company (MetLife)
New York
$316K
ZCM
95
Zebra Capital Management
Connecticut
$306K +$318K +17,720 New
AIG
96
American International Group
New York
$304K -$363K -20,259 -54%
D.E. Shaw & Co
97
D.E. Shaw & Co
New York
$298K -$2.89M -160,955 -90%
NFA
98
Nationwide Fund Advisors
Ohio
$284K +$4.93K +275 +2%
VRS
99
Virginia Retirement Systems
Virginia
$284K +$294K +16,400 New
MAM
100
Meeder Asset Management
Ohio
$281K -$4.43M -247,345 -94%

SCMP Hedge Fund Activity: Q4 2015 in Review

149 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Sucampo Pharmaceuticals, Inc. (SCMP) for Q4 2015, worth a combined $383M — down 18% from $468M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of SCMP and 21 opened new positions — a net loss of 4 holders — while 48 trimmed existing stakes and 62 added.

The largest buyer was Gotham Asset Management, adding an estimated $7.66M. The largest seller was Granahan Investment Management, exiting entirely with an estimated $32.1M sold.

  • 149 institutional investors held Sucampo Pharmaceuticals, Inc. (SCMP) as of Q4 2015, down from 154 in Q3 2015.
  • Funds reported $383M of Sucampo Pharmaceuticals, Inc. stock for Q4 2015, down 18% quarter-over-quarter.
  • 21 funds opened new Sucampo Pharmaceuticals, Inc. positions in Q4 2015 and 25 closed out, a net change of -4 holders.
  • The largest Sucampo Pharmaceuticals, Inc. buyer in Q4 2015 was Gotham Asset Management, an estimated $7.66M added.
  • The largest Sucampo Pharmaceuticals, Inc. seller in Q4 2015 was Granahan Investment Management, an estimated $32.1M sold.

Based on aggregated 13F filings for Q4 2015.